MetaCap

Molecular Partners (MOLN) vs Zura Bio (ZURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Molecular Partners (MOLN) has outperformed Zura Bio (ZURA) over the past year, losing 37.5% versus a loss of 74.4%. Molecular Partners is the larger company by market cap ($96.8 million vs $89.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MOLN-37.50%ZURA-74.37%
+102%+10%-83%
Nov 21, 20251 yearNov 20, 2026
MOLN-57.49%ZURA-96.84%
+70%-18%-105%
Mar 20, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MOLN versus ZURA key metrics
MetricMOLNZURA
Share price$2.53$0.9305
Market cap$96.80M$89.63M
1-day change-5.25%-2.30%
YTD return-42.07%-82.24%
1-year return-37.50%-74.37%
5-year return-77.87%—
EPS (TTM)$-1.68$-1.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-68.65M
52-week high$5.36$7.44
52-week low$2.52$0.919
Distance from 52-week high-52.89%-87.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+295.64%+759.75%
Average volume1.63K4.47M
Shares outstanding38.34M96.33M
Employees13440
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MOLN has outperformed ZURA by 36.9 percentage points over the past year.

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Zura Bio

ZURA stock →

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

MOLN vs ZURA FAQ

Which is bigger, Molecular Partners or Zura Bio?

Molecular Partners (MOLN) is larger, with a market capitalization of $96.80M compared with $89.63M for Zura Bio (ZURA).

Which stock has performed better over the past year, MOLN or ZURA?

MOLN returned -37.50% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.

Are Molecular Partners and Zura Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons